Related Experiment Videos
Myelography with metrizamide in occult spinal dysraphism
1Department of Neuroradiology, Newcastle General Hospital, England.
Acta Radiologica. Supplementum
|January 1, 1977
Summary
Metrizamide (Amipaque) shows promise for diagnosing spinal dysraphism, offering improved accuracy. Further research correlating myelography findings with surgical outcomes is needed for complete evaluation.
Area of Science:
- Neuroradiology
- Diagnostic Imaging
- Medical Devices
Background:
- Spinal dysraphism presents diagnostic challenges.
- Accurate imaging is crucial for surgical planning.
Purpose of the Study:
- To describe initial experiences with metrizamide (Amipaque) in spinal dysraphism.
- To evaluate the technique, myelographic appearance, and adverse reactions of metrizamide.
Main Methods:
- Case series describing the use of metrizamide (Amipaque).
- Analysis of myelographic appearance and patient-reported adverse reactions.
Main Results:
- Metrizamide (Amipaque) provided promising initial results.
- The contrast medium is believed to enhance diagnostic accuracy for spinal dysraphism.
Conclusions:
- Metrizamide (Amipaque) appears to be a valuable tool for diagnosing spinal dysraphism.
- Further clinical experience and correlation with surgical findings are necessary.